Pfizer is preparing to report the results of clinical trials of the COVID-19 antiviral pills experimental, from the pharmaceutical company they hope to be able to commercialize oral treatments against the coronavirus at some point.
The pharmaceutical companies Enanta, Pardes Biosciences, Shionogi & Co Ltdy Novartis AG have explained that they have developed antivirals specifically targeting coronavirus, but first, they seek to avoid potential deficiencies such as the need for several pills a day or known safety problems.
An easier way to protect yourself from the virus
Virologists have stressed that preventing COVID-19 through mass vaccination is the best way to control the pandemic. However, they have explained that the coronavirus will stay with us for a long time, and for that, we need more convenient treatments. ´
“We need to have oral alternatives for the suppression of this virus. We have people who are not vaccinated who get sick, people whose protection with the vaccine is decreasing and people who cannot get vaccinated, “explained Robert Schooley, an infectious disease specialist.
Anti-COVID antiviral pills before the end of the year
From Pfizer they have ensured that they could request the emergency approval for its COVID-19 antiviral pills this year. In addition, the rest of pharmaceuticals that are developing this type of drugs that can be ingested by way of prayer carry slower development than Pfizwe, so this could be the first to bring them to market.
–
